PMID- 22614884
OWN - NLM
STAT- MEDLINE
DCOM- 20121016
LR  - 20220317
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 6
IP  - 2
DP  - 2012 Aug
TI  - Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of 
      breast cancer.
PG  - 439-43
LID - 10.3892/mmr.2012.919 [doi]
AB  - Her2 proto-oncogene amplification and protein overexpression is observed in 
      20-40% of patients with breast cancer and plays a crucial role in invasive breast 
      cancer and its treatment. In the present study, we investigated samples from 131 
      patients with invasive breast carcinoma. In all cases, the 
      overexpression/amplification level of Her2 was determined using manual 
      immunohistochemistry (IHC) and/or automatic IHC, fluorescence in situ 
      hybridization (FISH), silver in situ hybridization (SISH) and quantitative 
      polymerase chain reaction (qPCR). Using various methods, we demonstrated 
      candidate methods for Her2 detection and their dependability. Our results 
      demonstrate that these methods are highly comparable for the detection of Her2 
      overexpression/amplification. It was also revealed that qPCR is a valuable tool 
      for the evaluation of Her2 gene overexpression/amplification. The results from 
      pPCR analysis positively correlated with the results from IHC and FISH analysis. 
      Moreover, in contrast to IHC or SISH/FISH, the results obtained by qPCR were not 
      encumbered with any subjective error on the part of the evaluator.
FAU - Tvrdik, D
AU  - Tvrdik D
AD  - Institute of Pathology, 1st Faculty of Medicine, Charles University and General 
      University Hospital, 12800 Prague 2, Czech Republic. Prague 2, Czech 
      RepublicE-mail:
FAU - Stanek, L
AU  - Stanek L
FAU - Skalova, H
AU  - Skalova H
FAU - Dundr, P
AU  - Dundr P
FAU - Velenska, Z
AU  - Velenska Z
FAU - Povysil, C
AU  - Povysil C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120517
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (DNA, Neoplasm)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biopsy, Needle/methods
MH  - Breast Neoplasms/*diagnosis/genetics/pathology
MH  - DNA, Neoplasm/*analysis/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Middle Aged
MH  - Polymerase Chain Reaction/*methods
MH  - Proto-Oncogene Mas
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - breast cancer
OT  - Her2
OT  - immunohistochemistry
OT  - fluorescence in situ hybridization
OT  - silver in situ hybridization
OT  - quantitative polymerase chain reaction
EDAT- 2012/05/23 06:00
MHDA- 2012/10/17 06:00
CRDT- 2012/05/23 06:00
PHST- 2012/02/08 00:00 [received]
PHST- 2012/05/15 00:00 [accepted]
PHST- 2012/05/23 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2012/10/17 06:00 [medline]
AID - 10.3892/mmr.2012.919 [doi]
PST - ppublish
SO  - Mol Med Rep. 2012 Aug;6(2):439-43. doi: 10.3892/mmr.2012.919. Epub 2012 May 17.